Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,340 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04010877 | Multiple CAR-T Cell Therapy Targeting AML | terminated | Phase 1 / Phase 2 | 10 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04019327 | A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer | terminated | Phase 1 / Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04085159 |
| Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis |
| terminated |
| Phase 1 / Phase 2 |
| 100 |
| Shenzhen Geno-Immune Medical InstituteOTHER |
| 1 |
| Aug 24, 2026 |
| clinicaltrials |
| NCT05262673 | NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL | terminated | Phase 1 | 10 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05277753 | NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL | terminated | Phase 1 | 10 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07193966 | NG2 and DLL3 CAR-T Cells Targeting Melanoma | terminated | Phase 1 / Phase 2 | 100 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT02392572 | ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome | terminated | Phase 1 / Phase 2 | 58 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04473781 | Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer | terminated | Phase 1 | 2 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05580770 | Mirdametinib + BGB-3245 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 23 | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyINDUSTRY | 2 | Aug 20, 2026 | clinicaltrials |
| NCT05497336 | A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer | terminated | Phase 1 | 8 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications(POTENTIATE) | terminated | Phase 1 | 85 | Boundless Bio, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07408089 | Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer(KOMODO-1) | terminated | Phase 1 | 8 | Boundless Bio, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07556757 | A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia | terminated | Phase 1 | 4 | ImmunityBio, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05435014 | T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 2 | T-ACE Medical Co., LtdINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT05083481 | A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors | terminated | Phase 1 | 226 | Astellas Pharma Global Development, Inc.INDUSTRY | 6 | Aug 14, 2026 | clinicaltrials |
| NCT02769962 | Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05572684 | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 97 | NextCure, Inc.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05101213 | Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients | terminated | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06391775 | Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy | terminated | Phase 1 / Phase 2 | 21 | GenmabINDUSTRY | 2 | Aug 11, 2026 | clinicaltrials |
| NCT04552704 | CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study | terminated | Phase 1 / Phase 2 | 3 | Tianhong LiOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05226507 | A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer | terminated | Phase 1 | 45 | Nuvectis Pharma, Inc.INDUSTRY | 2 | Aug 6, 2026 | clinicaltrials |
| NCT03869190 | Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) | terminated | Phase 1 / Phase 2 | 272 | Hoffmann-La RocheINDUSTRY | 7 | Aug 3, 2026 | clinicaltrials |
| NCT03287271 | ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK | terminated | Phase 1 / Phase 2 | 8 | Michael McHaleOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05307874 | Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors(EVICTION-2) | terminated | Phase 1 / Phase 2 | 56 | ImCheck Therapeutics, an Ipsen companyINDUSTRY | 3 | Jul 30, 2026 | clinicaltrials |
| NCT06021600 | A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine | terminated | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03695250 | BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 8 | Edward KimOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT04797702 | Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer.(CT32) | terminated | Phase 1 / Phase 2 | 6 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05322577 | A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.(FORTITUDE-103) | terminated | Phase 1 / Phase 2 | 72 | AmgenINDUSTRY | 5 | Jul 29, 2026 | clinicaltrials |
| NCT06622226 | A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | terminated | Phase 1 | 2 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT03598608 | Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) | terminated | Phase 1 / Phase 2 | 137 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Jul 28, 2026 | clinicaltrials |
| NCT03203525 | Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer | terminated | Phase 1 | 38 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT05616624 | ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers | terminated | Phase 1 / Phase 2 | 31 | Washington University School of MedicineOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT05826600 | A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically | terminated | Phase 1 / Phase 2 | 68 | iOmx Therapeutics AGINDUSTRY | 3 | Jul 24, 2026 | clinicaltrials |
| NCT06929260 | A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z | terminated | Phase 1 | 1 | AstraZenecaINDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT05180474 | GEN1047 for Solid Tumors - First in Human (FIH) Trial | terminated | Phase 1 / Phase 2 | 179 | GenmabINDUSTRY | 9 | Jul 23, 2026 | clinicaltrials |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 19 | NuCana plcOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06008483 | A Dose Finding Study to Treat Bone Tumor(s) | terminated | Phase 1 | 5 | QSAM Therapeutics, Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06022757 | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) | terminated | Phase 1 / Phase 2 | 12 | Evopoint Biosciences Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT00788307 | Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to Radiation Therapy | terminated | Phase 1 | 8 | Mayo ClinicOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT03786081 | Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer | terminated | Phase 1 / Phase 2 | 214 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 10 | Jul 22, 2026 | clinicaltrials |
| NCT05618613 | Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer(ELONA) | terminated | Phase 1 / Phase 2 | 4 | Context Therapeutics Inc.INDUSTRY | 1 | Jul 21, 2026 | clinicaltrials |
| NCT03148327 | Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy | terminated | Phase 1 / Phase 2 | 18 | Jonsson Comprehensive Cancer CenterOTHER | 2 | Jul 16, 2026 | clinicaltrials |
| NCT06028373 | A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas | terminated | Phase 1 | 38 | Antengene Biologics LimitedINDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06364696 | A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors | terminated | Phase 1 | 60 | Astellas Pharma IncINDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06528093 | A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy | terminated | Phase 1 | 8 | Boehringer IngelheimINDUSTRY | 6 | Jul 15, 2026 | clinicaltrials |
| NCT05828589 | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | terminated | Phase 1 | 51 | BeOne MedicinesINDUSTRY | 4 | Jul 14, 2026 | clinicaltrials |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | terminated | Phase 1 / Phase 2 | 14 | TCR2 TherapeuticsINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 24, 2026source: clinicaltrials